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Erythropoietin as an add-on treatment for
cognitive side effects of electroconvulsive
therapy: a study protocol for a randomized
controlled trial
Lejla Sjanic Schmidt1,6, Jeff Zarp Petersen1,2, Maj Vinberg1,3, Ida Hageman1,3, Niels Vidiendal Olsen4,5,
Lars Vedel Kessing1,3, Martin Balslev Jørgensen1,3† and Kamilla Woznica Miskowiak1,2,6*†
Abstract
Background: Electroconvulsive therapy (ECT) is the most effective treatment for severe depression, but its use is
impeded by its cognitive side effects. Novel treatments that can counteract these side effects may therefore improve
current treatment strategies for depression. The present randomized trial investigates (1) whether short-term add-on
treatment with erythropoietin (EPO) can reduce the cognitive side -effects of ECT and (2) whether such effects are
long-lasting. Further, structural and functional magnetic resonance imaging (MRI) will be used to explore the neural
underpinnings of such beneficial effects of EPO. Finally, the trial examines whether potential protective effects of EPO
on cognition are accompanied by changes in markers of oxidative stress, inflammation, and neuroplasticity.
Methods/design: The trial has a double-blind, randomized, placebo-controlled, parallel group design. Patients with
unipolar or bipolar disorder with current moderate to severe depression referred to ECT (N = 52) are randomized to
receive four high-dose infusions of EPO (40,000 IU/ml) or placebo (saline). The first EPO/saline infusion is administered
within 24 h before the first ECT. The following three infusions are administered at weekly intervals immediately after
ECT sessions 1, 4, and 7. Cognition assessments are conducted at baseline, after the final EPO/saline infusion (3 days
after eight ECT sessions), and at a 3 months follow-up after ECT treatment completion. The neuronal substrates for
potential cognitive benefits of EPO are investigated with structural and functional MRI after the final EPO/saline
infusion. The primary outcome is change from baseline to after EPO treatment (3 days after eight ECT sessions) in a
cognitive composite score spanning attention, psychomotor speed, and executive functions. With a sample size of
N = 52 (n = 26 per group), we have ≥ 80% power to detect a clinically relevant between-group difference in the
primary outcome measure at an alpha level of 5% (two-sided test). Behavioral, mood, and blood-biomarker data will be
analyzed using repeated measures analysis of covariance. Functional MRI data will be preprocessed and analyzed using
the FMRIB Software Library.
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Discussion: If EPO is found to reduce the cognitive side effects of ECT, this could have important implications for
future treatment strategies for depression and for the scientific understanding of the neurobiological etiology of
cognitive dysfunction in patients treated with ECT.
Trial registration: ClinicalTrials.gov, NCT03339596. Registered on 10 November 2017.
Keywords: Depression, Unipolar disorder, Bipolar disorder, Electroconvulsive therapy, Cognition, Cognitive side effects,
Erythropoietin, Functional magnetic resonance imaging
Background
Electroconvulsive therapy (ECT) is an effective, fast-
acting, and safe treatment for severe depression [1], but
it is associated with troublesome cognitive side effects
across episodic memory, attention, and executive func-
tions that persist for weeks [2, 3] to months after treat-
ment completion [4, 5]. Such cognitive side effects of
ECT are the greatest impediment to its prescription for
depression, making it reserved for only the most severely
ill patients [6]. Therefore, novel treatments that counter-
act these side effects have the potential to improve
current treatment strategies by allowing a greater num-
ber of severely ill patients to get earlier and more effect-
ive treatment with fewer cognitive side effects. However,
research efforts into identification of methods to attenu-
ate the cognitive side effects of ECT treatment without
hampering its clinical efficacy have thus far been unsuc-
cessful [7].
Erythropoietin (EPO) is a promising treatment for cog-
nitive dysfunction in mood disorders [8, 9] and for coun-
teracting ECT-induced cognitive side effects. EPO is not
only produced systematically in the kidneys, but is also
produced in the brain, where it mediates neuroprotec-
tion and development, modulates oxidative stress and
inflammation [10], and plays a key role in cognitive
functioning [11, 12]. Systemically administered EPO
crosses the blood-brain barrier and has been shown in
preclinical studies to mediate neuroprotection and neu-
roplasticity and to enhance cognitive functions when
given in high doses (≥ 500 IU/kg body weight) [13, 14].
Randomized controlled clinical studies suggest that
8–12 weeks of systemically administered high-dose
(40,000–48,000 IU) EPO improves attention, memory,
and executive functions in patients with treatment-
resistant depression (TRD) [9], bipolar disorder (BD) [8],
multiple sclerosis [15], or schizophrenia [16]. The cogni-
tive benefits of EPO treatment seem to result from direct
neurobiological actions rather than non-specific changes
in red blood cells. For example, randomized placebo-
controlled functional magnetic resonance imaging (fMRI)
studies by our group [17, 18] showed that a single high
dose (40,000 IU) of EPO vs. placebo enhanced memory-
relevant prefrontal and hippocampal activity in healthy
and depressed individuals without affecting red blood
cells. Consistent with this, our subsequent randomized,
placebo-controlled trials revealed that eight weekly infu-
sions of high-dose (40,000 IU) EPO vs. saline had mood-
independent beneficial effects on cognitive function in
patients with TRD (N = 40) and BD in remission (N = 44)
[8, 9]. These cognitive benefits were accompanied by
EPO-associated increase in neural activity within the
frontal and the parietal lobes during strategic encoding
and working memory tests [8, 9, 19]. Notably, EPO-
related memory improvement in these patients was asso-
ciated with reversal of hippocampal (cornu ammonis 1–3)
and subiculum volume loss [20], which is interesting in
light of ECT induction of hippocampal volume increase
(see, e.g., [21]). Importantly, these brain changes were inde-
pendent of changes in mood and lasted long term beyond
red blood cell normalization. Several neurobiological ac-
tions may underlie these beneficial cognitive effects of EPO
treatment, including activation of anti-inflammatory, anti-
apoptotic, and antioxidant signaling pathways [14, 22, 23]
and growth of dendrites, maturation of neural progenitor
cells, and upregulation of brain-derived neurotrophic factor
(BDNF) [24, 25]. Taken together, preliminary findings high-
light EPO as a candidate treatment for ECT-induced cogni-
tive deficits in mood disorders. This trial extends our
previous work by investigating for the first time whether
adjunctive EPO treatment can counteract the cognitive side
effects of ECT.
Aims and hypotheses
The present trial aims to investigate whether one primer
infusion of EPO/saline before ECT followed by three
weekly EPO/saline infusions during the course of ECT
counteracts cognitive side effects in patients receiving
ECT. Furthermore, we aim to investigate the neuronal
underpinnings of such potential effects of EPO with
structural and functional magnetic resonance imaging
(MRI) and the role of oxidative, inflammatory, and neu-
roendocrinological systems with blood and urine tests.
We hypothesize that EPO treatment will (1) counteract
ECT-induced decline in cognition (primary endpoint), which
will be accompanied by (2) increased subregional hippocam-
pal volume, (3) greater memory-related hippocampal activa-
tion and reinforcement of dorsolateral prefrontal activity
during memory encoding and working memory, and (4)
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changes in peripheral markers of inflammation, oxidative
stress, and neuroplasticity. Given preliminary evidence for
the beneficial effects of EPO on depression-relevant out-
comes [8, 13], a secondary hypothesis is that add-on EPO
treatment will produce greater, more sustained mood im-
provement than ECT treatment alone.
Methods/design
Participants and screening
A total of 52 patients with major depression (MDD) or
BD scheduled for ECT treatment will be recruited from
Psychiatric Centers in The Mental Health Services in the
Capital Region of Denmark. Half of the participants will
be randomized to receive active EPO treatment (n = 26),
while the other half will receive a placebo (saline) (n = 26).
Prior to enrollment, patients will be screened with the
Mini International Neuropsychiatric Interview (MINI)
[26] to confirm their International Statistical Classifica-
tion of Diseases and Related Health Problems (ICD-10)
diagnosis. Eligible patients have a diagnosis of MDD,
unipolar disorder (UD), or BD with current moderate to
severe depressive episode symptoms, a Hamilton De-
pression Rating Scale, 17 items (HDRS-17) score ≥ 17
[27], are 18–70 years of age, have fluent Danish skills,
and are able to provide informed consent. Exclusion cri-
teria are treatment under involuntary measures, previous
ECT within the last 3 months, other neuropsychiatric
conditions, alcohol or substance misuse disorder, or re-
cent suicide attempts. To ensure the safety of the EPO
treatment, patients are also excluded if they have a sig-
nificant medical condition (including diabetes, renal fail-
ure, heart disease, epilepsy, untreated/insufficiently
treated hypertension, malignancies, or thromboses), are
pregnant, use contraceptive medication, or have a family
history of thromboses or epilepsy, similar to our previ-
ous studies [28]. Pregnancy tests are mandatory for and
will be performed on female patients in their fertile age
before their inclusion in the trial. Patients will also be ex-
cluded if they are overweight (body mass index (BMI) > 30)
or have a body weight < 45/> 95 kg. Blood screening and
physical examinations are undertaken at baseline and
weekly during the 3-week EPO treatment period to ensure
patient safety. These exclusion criteria and weekly safety
monitoring prevented serious adverse events in our
previous EPO trials [8, 9, 28]. Written informed consent is
obtained by one of the named authors before inclusion.
The procedures are in accordance with the ethical stan-
dards of the Danish Research Ethics Committee for the
Capital Region.
Setting
Patients will be randomized to receive a total of four
intravenous infusions of either recombinant human EPO
(40,000 IU/ml; Epoetin alfa; Eprex, Janssen-Cilag) or a
placebo (1 ml NaCl) diluted with 100 ml saline (0.9%
NaCl) that is administered over 15 min. The first
infusion is given within 24 h before the first ECT, and
the following three infusions are administered immedi-
ately after ECT at weekly intervals (after ECT sessions 1,
4, and 7). The treatment and all the outcome assess-
ments will take place at Psychiatric Center Copenhagen,
Psychiatric Center Glostrup, or Psychiatric Center
Amager. Functional MRI is conducted at Copenhagen
University Hospital, Rigshospitalet. Participants will be
transported to and back from Copenhagen University
Hospital in a safe setting by two members of our re-
search team. Furthermore, to ensure the quality and the
reliability of the blood test results, all the blood samples
will be analyzed at the same laboratory, also at the
Copenhagen University Hospital, Rigshospitalet.
Study design and procedures
The trial has a randomized, double-blinded, placebo-
controlled, parallel group design. The study design and
procedures are summarized in Fig. 1. The Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) checklist is provided in Additional file 1.
Cognitive functions, mood symptoms, and blood and
urine markers of inflammation, oxidative stress, and
neuroplasticity will be assessed three times during the
trial. The first time will be at baseline, the second time
post-EPO treatment 3 days after ECT session 8 (patients
skip one ECT session day after eight ECTs to minimize
the confounding effects of acute side effects of ECT due
to anesthesia, etc.), and the third time at a 3 months
follow-up after ECT completion. In addition, the neur-
onal substrates for potential effects of EPO on cognition
are investigated with structural and fMRI after eight
ECT sessions (i.e., after three weekly EPO or saline infu-
sions). The rationale for assessing cognition and neur-
onal activity after eight ECTs is to ensure participation
of almost all patients, given our experience that > 95% of
patients need eight or more ECTs (unpublished observa-
tions from [29]) post-treatment. EPO/saline will be ad-
ministered when patients wake up following ECT. The
EPO doses are identical to those found to modulate neural
and cognitive function with short-term administration
[17] and to improve cognition with long-term treatment
[8, 9, 16, 30]. Concomitant medication is kept stable for
the duration of the study, unless the individual patient’s
psychiatrist deems it necessary to change medication.
EPO is kept at 2–8 °C during transport and storage
to minimize the risk of damaging the medication and
potential side effects. EPO will be dissolved in 100 ml
saline and administered intravenously over 15 min.
Patients will stay at the clinic for observation for at least
30 min after each infusion in case of acute severe adverse
events. In cases of significantly increased hematocrit (men
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TIMEPOINT Pre-intervention
Intervention
Follow-up 
(week 16
after ECT 
completion)
Baseline
3 weeks of 
treatment 
(week 4)
End-of-treatment
(5 days after ECT 
completion)
ENROLMENT:
Project information: 
written/oral communication
X
Written informed consent X
Eligibility assessment X
Randomisation X
ASSESSMENTS:
Mood rating X X X X X
Primary outcome
Cognitive composite score X X X
Secondary outcomes
AMI-SF X X X
RAVLT X X X
Tertiary outcomes
AMI-SF X X X
RAVLT X X X
TMT-B X X X
WAIS-III LNS X X X
RBANS Coding X X X
Verbal Fluency (“D”) X X X
RVP (CANTAB) X X X
HDRS-17 X X X
BDI-21 X X X
COBRA X X X
Other measures
CTQ X
Functional magnetic 
resonance imaging
X
Blood tests for biomarkers X X X
Fig. 1 Schedule of enrollment, interventions, and assessments. Abbreviations: AMI-SF Columbia University Autobiographical Memory Interview-Short
Form, RAVLT Rey Auditory Verbal Learning Test, TMT-B Trail Making Test Part B, WAIS-III LNS Wechsler Adult Intelligence Scale Version III Letter-Number
Sequencing, RBANS Coding Repeatable Battery for the Assessment of Neuropsychological Status Coding, RVP Rapid Visual Processing (CANTAB Cambridge
Cognition Ltd.), HDRS-17 Hamilton Depression Rating Scale, 17-item version, BDI-21 Beck Depression Inventory, 21 items, COBRA Cognitive Complaints in
Bipolar Disorder Rating Assessment, CTQ Childhood Trauma Questionnaire
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> 50%, women > 48%) at two consecutive blood test mea-
surements within the same week, bloodletting (450 ml)
will be performed on a weekly basis with no cessation of
treatment until hematocrit values are normalized. In the
case of a significant increase in thrombocytes (> 400
billion/L) or a drop in reticulocytes (< 1‰), two repeated
controls will be performed in the following week. If the
values stay abnormal, the patient will be withdrawn from
further study participation and monitored with weekly
medical examinations and blood samples until he or she is
stabilized. If deemed necessary by the medic responsible
for patient safety, the patient might be hospitalized for
observation. Procedures for breaking randomization codes
are established in the case of serious adverse events poten-
tially or directly related to the medical intervention. These
procedures will be followed if knowledge of the patient’s
medical treatment will have implications for treatment of
the observed serious adverse events. The principal investi-
gator or any medical doctor responsible for the patient is
able to decide whether to break emergency envelopes for
potentially affected patients.
ECT procedures
ECT will be administered three times per week
(Mondays, Wednesdays, and Fridays), according to the
standard protocol of the Mental Health Services in the
Capital Region of Denmark. Patients are anesthetized
with thiopental, and succinylcholine is administered for
muscle relaxation. Bitemporal (BT) electrode placement
with an energy dosage 1.5 times above the seizure
threshold can be changed to right unilateral (RUL) treat-
ment in the case of severe cognitive side effects; this is
decided by the treating psychiatrist. The dosing strategy
with the initial dose is based on patient age (charge
[percentage of 500 millicoulombs] = 50% of the age).
Subsequent treatments are dose-titrated based on
seizure quality. The end of treatment is determined by
the treating psychiatrist.
Randomization and blinding
Power calculation and block randomization have been
conducted by the independent Pharma Consulting
Group AB (www.pharmaconsultinggroup.com) using
PROC POWER and the SAS code in the Statistical
Analysis Software (SAS) version 3. Treatment groups
are stratified for age (≥ 40 or < 40) and gender. At the
time of inclusion, gender and date of birth are regis-
tered to determine the appropriate stratum for each
included patient. Study identification numbers are
provided consecutively within each stratum. Patients
and outcome assessors are blinded to treatment as-
signment, and blinding is maintained throughout the
study period and the data analysis. The randomization
list is kept in a locked filing cabinet for which only
the person preparing the study medication and the
principal investigator have a key. Preparation of study
medication is performed to ensure double-blinding at the
time of infusion: 1 ml recombinant human EPO (Eprex;
40,000 IU; Janssen-Cilag) or saline (NaCl 0.9%) kept at a
temperature of 5–8 °C is injected into a standard 100 ml
saline (NaCl 0.9%) infusion bag, which is then given to the
study nurse or physician administering the medication.
Double-blinding is further ensured by EPO being a color-
less liquid undistinguishable from saline. Weekly monitor-
ing of blood tests and any side effects of EPO treatment
are performed by a physician not involved in outcome
measure assessments. Participants are instructed to not
reveal any symptoms or potential physical side effects as-
sociated with EPO treatment to study personnel involved
in outcome assessments. The Good Clinical Practice
(GCP) Unit at Copenhagen University Hospital (www.
gcp-enhed.dk/kbh) will monitor that blinding is main-
tained. Unblinding for individual participants is permitted
for safety reasons in cases of side effects or serious adverse
events likely or directly related to the study medication.
Revealing a patient’s allocated intervention during the trial
involves opening his or her sealed randomization enve-
lope. In these cases, it is the sovereign decision of LSS,
MBJ, MV, or LVK as to whether the randomization code
should be broken.
Outcome assessments
For an overview of frequency and timing of outcome
assessment, see Fig. 1.
The primary outcome comprises change from baseline
to post-treatment on a cognitive composite score asses-
sing attention, verbal learning and memory, and execu-
tive functions. We have found an improvement on this
“speed of complex cognitive processing” composite
measure in our previous EPO cognition trial across pa-
tients with BD and TRD after 8 weeks of weekly EPO
treatment [31]. In the present study, we therefore in-
clude the same global cognition score as the primary
outcome measure. This consists of the following six
neuropsychological tests, spanning verbal memory, at-
tention, and executive functions: Rey Auditory Verbal
Learning Test (RAVLT) [32, 33], the Repeatable Battery
for the Assessment of Neuropsychological Status
(RBANS) Coding [34], Verbal Fluency with the letter “D”
[35], Wechsler Adult Intelligence Scale (WAIS)-III
Letter-Number Sequencing [36], Trail Making Test Part
B (TMT-B) [37], and Rapid Visual (Information) Pro-
cessing (RVP) from the Cambridge Neuropsychological
Test Automated Battery (CANTAB Cognition Ltd.). The
secondary outcomes are retrograde autobiographical
memory measured with the Columbia University Auto-
biographical Memory Interview-Short Form (AMI-SF)
[38, 39] and verbal learning and memory assessed with
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the RAVLT [32, 33]. The tertiary outcomes comprise (1)
individual neuropsychological tests of the cognitive com-
posite score, (2) depression severity assessed with the
HDRS-17 [27] and the Beck Depression Inventory, 21
items (BDI-21 [40]), respectively, (3) subjectively rated
cognitive complaints assessed with the Cognitive Com-
plaints in Bipolar Disorder Rating Assessment (COBRA)
[41], (4) cognition-related activity in key neuronal cir-
cuits and hippocampal structure, and (5) blood- and
urine-based markers of inflammation, oxidative stress,
and neuroplasticity. History of early life stress will be
assessed with the Childhood Trauma Questionnaire
(CTQ [42]) at the eligibility assessment.
To reduce risks of learning effects at follow-up neuro-
psychological assessments, we administer alternate ver-
sions of the RAVLT (original list AB, GeAB, and Cr-AB)
and RBANS Coding (version A and B) [34] in a counter-
balanced order within each stratum.
Peripheral and neural biomarkers and genotyping
To investigate whether there is a significant difference be-
tween EPO- and saline-treated patients in structural and
functional measures of cognition-relevant neural regions,
including the hippocampus and the frontal lobes, patients
undergo a structural and fMRI scan after 3 weeks of
weekly EPO or placebo infusions (i.e., at week 4). During
fMRI (approximately 45 min duration) patients are given
three neurocognitive tests: (1) the Autobiographical Mem-
ory Test [43] adapted for fMRI assessment [13, 44], (2) a
hippocampus-dependent picture memory retrieval test
that is sensitive to the effects of EPO on hippocampal re-
sponse [17], and (3) a Spatial N-back working memory
test from our previous study [19]. Furthermore, we will
examine whether the potential protective effects of EPO
on cognition are accompanied by changes in markers of
oxidative stress, inflammation, or neuroplasticity in blood
and urine. Specifically, blood samples will be analyzed to
investigate whether changes in the peripheral biomarker,
high-sensitivity C-reactive protein (hsCRP), are important
for cognitive benefits of EPO treatment.
Biochemistry
Since EPO has anti-inflammatory actions [14, 22, 23]
and compiling evidence indicates that major depressive
disorder (MDD) is associated with increased low-grade
neuroinflammation [45–47], we will explore the effects
of add-on treatment with EPO on systemic markers of
inflammation. Blood and urine samples will be trans-
ferred to the Neuropsychiatric Laboratory, Department
O, Rigshospitalet, and stored at − 80 °C until use.
Measurements will be performed at the Neuropsychiatric
Laboratory and at the Department of Clinical
Pharmacology, Rigshospitalet.
Statistical analyses
The statistical significance threshold is considered to be
p < 0.05 (two-tailed). Behavioral, mood, and biomarker
data will be analyzed using a mixed models design and
an intention-to-treat (ITT) approach. Structural and
functional imaging data will be collected using a 3 T MR
scanner operating at Copenhagen University Hospital,
Rigshospitalet. Resting state and task-related fMRI data
will be preprocessed and analyzed using the FMRIB
Expert Analysis Tool (FEAT) and the ‘randomize’ algo-
rithm integrated in the FMRIB Software Library (FSL),
www.fmrib.ox.ac.uk/fsl. We will adjust for potential dif-
ferences in demographical and clinical parameters at
baseline. All statistical analyses will be run using the
Statistical Package for Social Sciences (SPSS, version 23,
IBM Corporation, Armonk, NY).
Sample size and power calculation
The sample size and statistical power have been calculated
by Pharma Consulting Group AB using PROC POWER
and the SAS code in SAS version 3. We estimate that a
clinically relevant differential change in the cognitive com-
posite score between the EPO and placebo groups is 0.4
standard deviations (SD; corresponding to a moderate ef-
fect size), with an SD of the mean change of 0.5. This is
consistent with the recommendations of the International
Society for Bipolar Disorders (ISBD) cognition task force
[48]. Specifically, the task force noted that a differential
change between groups of 0.2–0.4 SD on a global compos-
ite score represents a potentially clinically relevant change,
as this may translate into moderate to large functional im-
provement in patients with mood disorders [48]. In our
previous 8-week EPO trial, the difference between EPO
and the saline groups regarding change in the cognitive
composite score from baseline to post-treatment was 0.5
SD [31]. Based on the ISBD task force recommendations
and our previous findings regarding the effects of longer
term EPO treatment, we estimate that a sample size of N
= 52 (n = 26 per group) will reach a ≥ 0.8 power to detect a
similar clinically relevant differential change of 0.4 SD in
the primary outcome measure (the cognitive composite
score) with an SD of this change of 0.5 between the two
groups at an alpha level of 5% (two-sided test) [31].
The study is also powered to investigate differences in
fMRI blood-oxygen-level dependent (BOLD) response in
key neural networks based on our previous fMRI studies,
in which sample sizes of 30 age- and gender-matched
participants (n = 15 per group) had a power of > 0.8 to
show drug-related effects on task-related neural re-
sponse (e.g., memory and executive function) at an alpha
level of p < 0.05 [19, 31]. In the current trial, the inclu-
sion of 52 participants (n = 26 per treatment group)
therefore ensures sufficient statistical power to detect
EPO-related effects on neural activity.
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Data management and monitoring
Personal information is obtained at enrollment or from
patient records, if patients are unable to provide the ne-
cessary information. Written informed consent forms
will be signed and kept in a locked filing cabinet, and a
password-protected list that matches participant ID
numbers with personal information will be stored iso-
lated from pseudo-anonymized data. A list matching
participants’ personal information with their ID number
will be deleted, while consent forms are maculated
10 years after study completion, after which all data will
be completely anonymized. All named authors will have
access to the final dataset. Pseudo-anonymized data will
be entered in the Research Electronic Data Capture
(REDCap) database, which fulfills the Danish data law
for keeping patients’ records and meets GCP require-
ments for data management. Study personnel respon-
sible for outcome assessments and evaluation of the
findings are blinded to study medication until the data
analyses are completed. Consequently, blood sample re-
sults and lists of potential adverse effects are registered
in REDCap slots to which only medical doctors respon-
sible for patient safety and the person involved in blind-
ing of the study medication have access. Data quality is
heightened by verification of data entered by outcome
assessors and range restrictions on values from neuro-
psychological test and questionnaire scores. In addition,
REDCap has a logging module which enables tracking of
the entered data. As an additional precaution, registra-
tion of all primary outcome data will be double-checked
by JZP.
Participant retention
All patients are offered feedback on changes of their
cognition measured with neuropsychological tests once
they have completed the 3 months follow-up assessment.
This will give participants insight into whether potential
experiences of cognitive side effects reflect objectively
verified decline or may be due to residual mood symp-
toms. Travel expenses with public or private transporta-
tion on days of assessments are reimbursed for all
participants. Furthermore, patients will benefit from the
extra care they receive from study nurses, psychologists,
and medical doctors during their participation.
Discussion
Summary
Electroconvulsive therapy (ECT) is a safe, effective, and
fast-acting treatment option for severe depressive
disorders, but its use is impeded by cognitive adverse
effects. Novel treatments that can counteract the ECT-
associated cognitive side effects may therefore improve the
current treatment strategies for depression. The present
trial investigates for the first time whether short-term
(four doses) add-on treatment with erythropoietin (EPO)
over the first 3 weeks of ECT can counteract (or reduce)
cognitive side effects of ECT and the neuronal underpin-
nings of such effects.
Limitations
The extensive exclusion criteria for receiving EPO treatment
are necessary to ensure patient safety. However, they limit
the recruitment rate and the generalizability of findings, as
the study sample will not reflect the full range of somatic
and psychiatric comorbidities, treatment response, and func-
tioning of ECT-referred MDD and BD patients in the clinic.
Furthermore, concomitant pharmacological treatment may
influence patients’ cognitive functioning before, during, and
after study participation [49], thus potentially confounding
the neuropsychological test and fMRI task data. To
minimize such confounding effects, medication is kept
stable for the duration of the study, if possible, and medica-
tion use is carefully recorded such that potential interaction
effects with EPO can be evaluated in post hoc analyses.
Study feasibility
Approximately 200 patients with non-psychotic unipolar
disorder aged 18–60 years received ECT at the Psychiatric
Center Copenhagen during a 6-year period from 2008 to
2014 [50]. In our double-blinded randomized trials of the
effects of 8 weeks of EPO treatment, we included 84
patients with mood disorders over a 3-year period (2009–
2012) [8, 9]. Given this and our collaboration with other
hospitals within the Psychiatric Center Copenhagen, we
consider recruitment of 52 patients over 28 months for
the present study feasible.
Safety procedures and monitoring
EPO is commonly used in the treatment of anemia and
has a good safety profile when carefully monitored.
Nevertheless, hematopoietic effects of repeated EPO ad-
ministration are associated with increased risk of hyper-
tension and blood clotting [51]. For instance, EPO has
been associated with increased mortality in severely ill
stroke patients with a previous history of thrombo-
embolic disease, including patients given thrombolytic
treatment [52, 53]. To ensure patient safety in this trial,
we have extensive exclusion criteria to exclude partici-
pants at increased risk of thromboembolic events. There
is also some concern that EPO may increase the risk of
tumor growth, although the evidence for this is unclear
[54]. The rare condition called pure red cell aplasia
(PRCA) has been detected with subcutaneous injections
and poor packaging of the EPO medicine. However, its
incidence rate has fallen to 0.3/100,000 patient years
[55–57]. Given thorough adherence to the exclusion cri-
teria and the weekly safety monitoring, we evaluate the
risk of such severe side effects and adverse events of
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EPO treatment in this trial to be extremely low. Since
reticulocyte counts constitute the first indicator of
PRCA, these counts will be carefully monitored. We
observed no serious adverse events of 8 weekly EPO in-
fusions in the proposed dose and administration form in
our previous studies including patients with mood disor-
ders [8, 9]. EPO-related hematocrit levels increased to
an extent that necessitated bloodletting in 5 (14%) of the
35 EPO-treated patients in weeks 3–8 (only 1 in week 3)
, which corresponds to observations by Ehrenreich et al.
[15, 16]. We discontinued EPO treatment in six patients
(17%) after 5–7 weeks due to thrombocyte level increase.
Since we give only 3 weeks of EPO treatment in the
present study (four doses), we do not expect such side
effects. Accordingly, safety monitoring involves thorough
medical examinations, blood pressure measures, blood
sampling, electrocardiography (ECG), and the mea-
surement of additional safety parameters at baseline,
weekly during the study, and at 3 weeks after EPO/pla-
cebo treatment completion. Patients will be informed
of all potential adverse effects before randomization
and told that iron supplements (which increase
hematocrit levels) are prohibited. Although the risk of
potential thrombosis or suspected PRCA is low, partici-
pants will be given a pocketsize plastic card with
instructions about what to do and contact details to
medical doctors at the local emergency department in
case of these symptoms.
Ethical considerations
Risks and disadvantages of participating in the study are
minimal based on our previous EPO trials [8, 9] and the
described exclusion criteria, precautions, and the estab-
lished treatment plan in cases of side effects or adverse
events. Indeed, the lack of effective treatments for ECT-
related cognitive side effects and preliminary evidence
for neurotrophic and cognitive properties of EPO under-
lines the benefits of being randomized to the active
treatment group. Randomization to placebo for half of
the patients will be disappointing compared to receiving
active treatment. Nevertheless, the use of a placebo
group is necessary for assessing the potential pro-
cognitive efficacy of EPO. It is demanding for these very
ill patients to undergo cognition and fMRI assessments.
Therefore, we have limited cognition assessments to
1½ h twice during the study period and once at the
3 months follow-up, and fMRI scan assessment to
45 min once during the study period. Although the fMRI
procedure is safe and non-invasive, some patients may
experience claustrophobia and/or anxiety during scans.
Patients may benefit from the extra care and close con-
tact with medical doctors, psychologists, and a research
nurse during their participation, which has previously re-
vealed beneficial effects [58].
Perspectives
If EPO is found to alleviate cognitive side effects of ECT,
this could have important implications for future
treatment strategies for severe depression and for the
scientific understanding of the neurobiological etiology
of ECT-related cognitive decline in patients treated
with ECT.
Trial status and dissemination
Participant enrollment was initiated in June 2017 and
is expected to be completed by December 2019.
Findings will be disseminated in peer-reviewed scien-
tific journals and presented at scientific meetings and
conferences. Author eligibility is assessed with the
Vancouver Convention.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (PDF 132 kb)
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